Arch Biopartners, Inc. (ARCH.V)
0.89
+0.10
(+12.66%)
CAD |
TSXV |
Feb 10, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 59.57M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -52.15% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -0.7317 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 82.20% |
Profile
| Arch Biopartners, Inc. is a therapeutic biotech company developing novel, on-target drugs for kidney injury and disease. Its portfolio includes programs in both acute kidney injury (AKI) and chronic kidney disease (CKD), two serious conditions that affect hundreds of millions of patients worldwide. Arch's drug candidates, LSALT peptide and Cilastatin, are in Phase II clinical trials and have the potential to significantly improve outcomes for patients at risk of AKI. The company is also advancing its pre-clinical CKD platform targeting IL-32, a non-classical cytokine directly implicated in diabetic kidney disease, the main cause of kidney failure worldwide. The company was founded by Richard Gabriel Muruve and Daniel Muruve on March 4, 1983 and is headquartered in Toronto, Canada. |
| URL | http://www.archbiopartners.com |
| Investor Relations URL | N/A |
| HQ State/Province | Ontario |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Arch Biopartners, Inc. is a therapeutic biotech company developing novel, on-target drugs for kidney injury and disease. Its portfolio includes programs in both acute kidney injury (AKI) and chronic kidney disease (CKD), two serious conditions that affect hundreds of millions of patients worldwide. Arch's drug candidates, LSALT peptide and Cilastatin, are in Phase II clinical trials and have the potential to significantly improve outcomes for patients at risk of AKI. The company is also advancing its pre-clinical CKD platform targeting IL-32, a non-classical cytokine directly implicated in diabetic kidney disease, the main cause of kidney failure worldwide. The company was founded by Richard Gabriel Muruve and Daniel Muruve on March 4, 1983 and is headquartered in Toronto, Canada. |
| URL | http://www.archbiopartners.com |
| Investor Relations URL | N/A |
| HQ State/Province | Ontario |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |